Total Payments
$18,061
2024 Payments
$4,030
Companies
50
Transactions
720
Medicare Patients
3,389
Medicare Billing
$473,756
Payment Breakdown by Category
Food & Beverage$13,614 (75.4%)
Travel$2,212 (12.2%)
Consulting$1,500 (8.3%)
Research$250.00 (1.4%)
Education$237.85 (1.3%)
Other$237.60 (1.3%)
Gifts$9.72 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,614 | 704 | 75.4% |
| Travel and Lodging | $2,212 | 3 | 12.2% |
| Consulting Fee | $1,500 | 1 | 8.3% |
| Unspecified | $250.00 | 5 | 1.4% |
| Education | $237.85 | 4 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $214.29 | 1 | 1.2% |
| Entertainment | $23.31 | 1 | 0.1% |
| Gift | $9.72 | 1 | 0.1% |
Payments by Type
General
$17,811
715 transactions
Research
$250.00
1 transactions
Ownership
$0
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,605 | 227 | $0 (2024) |
| GastroGPO, LLC | $1,971 | 6 | $0 (2024) |
| Shionogi Inc | $1,683 | 6 | $0 (2019) |
| Janssen Biotech, Inc. | $1,672 | 106 | $0 (2024) |
| Boston Scientific Corporation | $1,491 | 13 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $678.33 | 37 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $652.22 | 38 | $0 (2024) |
| Celgene Corporation | $547.26 | 30 | $0 (2024) |
| Enterra Medical, Inc. | $521.01 | 4 | $0 (2024) |
| PFIZER INC. | $449.11 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,030 | 135 | Boston Scientific Corporation ($1,013) |
| 2023 | $4,639 | 136 | GastroGPO, LLC ($1,971) |
| 2022 | $1,949 | 116 | ABBVIE INC. ($445.68) |
| 2021 | $989.74 | 66 | Janssen Biotech, Inc. ($253.13) |
| 2020 | $409.91 | 28 | AbbVie Inc. ($174.71) |
| 2019 | $1,182 | 75 | AbbVie, Inc. ($350.96) |
| 2018 | $3,224 | 88 | Shionogi Inc ($1,616) |
| 2017 | $1,637 | 76 | AbbVie, Inc. ($397.39) |
All Payment Transactions
720 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: LIVER DISEASE | ||||||
| 12/18/2024 | Enterra Medical, Inc. | — | Food and Beverage | In-kind items and services | $20.80 | General |
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.82 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.76 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Immunology | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/22/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $193.95 | General |
| 11/21/2024 | Boston Scientific Corporation | — | Travel and Lodging | In-kind items and services | $464.95 | General |
| 11/21/2024 | Boston Scientific Corporation | — | Travel and Lodging | In-kind items and services | $244.56 | General |
| 11/21/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/19/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Immunology | ||||||
| 11/13/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $23.64 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | PFIZER INC. | VELSIPITY (Drug), XELJANZ | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $214.29 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/05/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/05/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $2.19 | General |
| 11/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Gastroenterology | ||||||
| 11/04/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $3.10 | General |
| 10/30/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: Immunology | ||||||
| 10/30/2024 | VIVUS LLC | QSYMIA (Drug) | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: INTERNAL MEDICINE | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol (CIMZIA) For Crohn's Disease | UCB Biosciences Inc. | $250.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 939 | 7,040 | $891,290 | $206,769 |
| 2022 | 13 | 781 | 883 | $384,818 | $86,987 |
| 2021 | 12 | 923 | 1,015 | $478,334 | $106,765 |
| 2020 | 13 | 746 | 829 | $325,809 | $73,234 |
Total Patients
3,389
Total Services
9,767
Medicare Billing
$473,756
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J3380 | Injection, vedolizumab, 1 mg | Office | 2023 | 12 | 6,000 | $408,000 | $104,151 | 25.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 152 | 153 | $163,251 | $31,252 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 206 | 268 | $58,156 | $23,608 | 40.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 84 | 84 | $27,888 | $9,530 | 34.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 138 | 141 | $95,880 | $7,664 | 8.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 82 | 87 | $12,876 | $5,690 | 44.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 40 | 73 | $10,658 | $4,511 | 42.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 26 | 26 | $20,228 | $4,434 | 21.9% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 36 | 37 | $25,937 | $3,375 | 13.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 44 | 44 | $37,268 | $3,187 | 8.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 51 | 51 | $11,169 | $2,927 | 26.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $5,343 | $1,761 | 33.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 18 | 18 | $5,004 | $1,745 | 34.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $4,598 | $1,369 | 29.8% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 20 | $2,920 | $1,007 | 34.5% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 14 | 14 | $2,114 | $559.87 | 26.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 217 | 285 | $61,845 | $24,340 | 39.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 108 | 108 | $115,236 | $21,276 | 18.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 73 | 73 | $24,236 | $8,218 | 33.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 103 | 105 | $69,426 | $6,337 | 9.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 29 | 29 | $22,562 | $5,220 | 23.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 42 | 70 | $10,220 | $3,886 | 38.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 60 | $8,880 | $3,746 | 42.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 38 | 38 | $32,186 | $3,711 | 11.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 26 | 26 | $7,228 | $2,719 | 37.6% |
About Dr. Kumar Gutta, M.D
Dr. Kumar Gutta, M.D is a Gastroenterology healthcare provider based in Fort Worth, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831180413.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kumar Gutta, M.D has received a total of $18,061 in payments from pharmaceutical and medical device companies, with $4,030 received in 2024. These payments were reported across 720 transactions from 50 companies. The most common payment nature is "Food and Beverage" ($13,614).
As a Medicare-enrolled provider, Gutta has provided services to 3,389 Medicare beneficiaries, totaling 9,767 services with total Medicare billing of $473,756. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Fort Worth, TX
- Active Since 11/02/2005
- Last Updated 02/16/2017
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1831180413
Products in Payments
- Mulpleta (Drug) $1,672
- STELARA (Biological) $1,613
- RINVOQ (Biological) $971.10
- Humira (Biological) $863.18
- ZEPOSIA (Drug) $636.85
- ENTYVIO (Biological) $499.20
- XIFAXAN (Drug) $493.35
- DUPIXENT (Biological) $462.01
- Cimzia (Drug) $390.10
- SKYRIZI (Biological) $336.96
- HUMIRA (Biological) $275.47
- VELSIPITY (Drug) $248.80
- Trulance (Drug) $244.52
- Sucraid (Drug) $239.72
- Linzess (Drug) $239.24
- LINZESS (Drug) $229.76
- VIBERZI (Drug) $215.58
- INJECTAFER (Drug) $182.91
- RENFLEXIS (Drug) $182.01
- OMVOH (Drug) $178.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Fort Worth
Dr. Joseph Shelton, M.d, M.D
Gastroenterology — Payments: $73,563
Gastroenterology $73,563
Dr. Themistoklis Kourkoumpetis, Md, Mph, MD, MPH
Gastroenterology — Payments: $71,587
Gastroenterology $71,587
Fatema Uddin, Md, MD
Gastroenterology — Payments: $56,218
Gastroenterology $56,218
Dr. Thomas Dewar, M.d, M.D
Gastroenterology — Payments: $11,704
Gastroenterology $11,704
Dr. Susan Moster, D.o, D.O
Gastroenterology — Payments: $11,037
Gastroenterology $11,037
Dr. Syed Sadiq, M.d, M.D
Gastroenterology — Payments: $10,979
Gastroenterology $10,979